Targeted Oncology2d
CAR T and CRS Adverse Events Considered in Relapsed Multiple Myeloma
During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed CAR T-cell therapy as third-line therapy for ...
The Pharma Letter2d
Super-blockbuster Darzalex gets another EU nod
Johnson & Johnson has secured European approval for the subcutaneous formulation of Darzalex, combined with bortezomib, lenalidomide, and dexamethasone, for newly diagnosed multiple myeloma patients ...
HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today provided an update following a decision by the Opposition Division of the ...
Pharmabiz2d
Janssen-Cilag’s Darzalex -SC based quadruplet regimen gets European approval to treat patients with newly diagnosed MM who are transplant-eligible
Janssen-Cilag’s Darzalex -SC based quadruplet regimen gets European approval to treat patients with newly diagnosed MM who are transplant-eligible: Beerse, Belgium Thursday, Oct ...
J&J’s Darzalex combination gains expanded label for multiple myeloma in Europe
Darzalex will now be available to patients with newly diagnosed multiple myeloma eligible for autologous stem cell transplant ...
manilatimes3d
Verkkokauppa.com's change negotiations completed - the organization is renewed to improve operational efficiency
The change negotiations that started on 4 September 2024 covered approximately 220 people. At the beginning of the negotiations, the planned measures were estimated to lead to the termination of up to ...
Targeted Oncology4d
Roundtable Roundup: Early-Line Use of CAR T-cell Therapy in Multiple Myeloma
In separate, live virtual events, Doris Hansen, MD, and Leyla O. Shune, MD, discuss options for a patient with ...